EVLVW — Evolv Technologies Holdings, Inc.

Evolv Technology (EVLVW) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $38.5 million, up 32% year-over-year.
• Full Year Revenue: $145.9 million, reflecting a 40% increase year-over-year.
• Annual Recurring Revenue (ARR): $120.5 million, a 21% growth year-over-year.
• Adjusted EBITDA: Positive $1.8 million in Q4, with a margin of 4.7%. Full year adjusted EBITDA was $11.1 million (7.6% margin), a significant improvement from a loss of $21 million in 2024.
• Remaining Performance Obligation (RPO): $293.4 million, up 13% year-over-year.
• Cash Position: Increased by $12.8 million sequentially to $69 million, indicating strong cash collection and working capital management.

2. Strategic Updates and Business Highlights

• Evolv Technology has deployed 8,000 systems, screening over 4 million people daily, with a total of 4 billion people screened since the launch of Evolv Express.
• The company added over 60 new customers in Q4, totaling over 1,200 customers globally, with a strong focus on education, healthcare, and sports sectors.
• Notable partnerships include a designation as a preferred provider by the American Hospital Association, reinforcing its position in the healthcare market.
• The introduction of the eXpedite autonomous bag screening solution has gained traction, with 65 customers adopting it, enhancing the company's product portfolio.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected between $172 million and $178 million, an increase from previous guidance of $160 million to $165 million.
• ARR Growth Expectation: Anticipated growth of 20% to 25%, with a target of $145 million to $150 million in ARR by the end of 2026.
• The company expects to end 2026 with over 10,000 units deployed and aims for adjusted EBITDA margins to expand into the high single digits.

4. Challenges and Points of Concern

• Gross Margin Decline: Adjusted gross margin decreased to 50% in Q4 from 62% the previous year, attributed to the shift to direct fulfillment and an accrual for service costs.
• Product Revenue Fluctuations: A slight decline in product revenue from Q3 due to a significant prior deal and timing issues with subscription contracts.
• Cash Flow Variability: While Q4 showed strong cash flow, the company anticipates challenges in the first half of 2026 due to prior year incentive payments impacting cash flow dynamics.

5. Notable Q&A Insights

• Customer Acquisition Mix: The company maintains a balanced mix of approximately 50% new customers and 50% existing customer expansions.
• Impact of AHA Partnership: The partnership with the American Hospital Association is expected to accelerate hospital deals, particularly in light of regulatory trends mandating weapon screening.
• Hiring Plans: Evolv plans to invest in R&D and sales to support growth, while managing expenses to ensure that revenue growth outpaces expense growth.
• Plexus Relationship: The company remains on track for full ramp-up with Plexus in the second half of 2026, which is expected to provide a tailwind to gross margins.

Overall, Evolv Technology demonstrated strong growth in Q4 2025, with positive momentum heading into 2026, despite some challenges related to gross margins and cash flow variability. The strategic focus on expanding its customer base and enhancing its product offerings positions the company well for future growth.